专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2858569A1 SYSTEM AND METHOD OF MONITORING AND CONTROL OF ULTRAFILTRATION VOLUME DURING PERITONEAL DIALYSIS USING SEGMENTAL BIOIMPEDANCE 有权
标题翻译：系统ZURÜBERWACHUNGUND STEUERUNG VON ULTRAFILTRATIONSVOLUMINAWÄHRENDEINER PERITONEALDIALYSE MITTELS SEGMENTALER BIOIMPEDANZ
公开(公告)号：EP2858569A1
公开(公告)日：2015-04-15
申请号：EP13800441.1
申请日：2013-06-07
申请人： Fresenius Medical Care Holdings, Inc.
发明人： ZHU, Fansan , LEVIN, Nathan, W.
IPC分类号： A61B5/1455 , A61B5/00 , A61B5/05 , A61B6/00 , A61M1/14 , A61M1/28 , A61M5/142 , G01N21/35
CPC分类号： A61M1/28 , A61B5/1451 , A61B5/4848 , A61B5/6866 , A61M1/281 , A61M1/282 , A61M1/284 , A61M2205/17 , A61M2205/18 , A61M2205/3317 , A61M2205/3344 , A61M2205/3379 , A61M2205/3569 , A61M2205/3592 , A61M2210/1017 , A61M2230/005
摘要： A peritoneal dialysis (PD) system for infusing a volume of PD solution into a patient's peritoneal cavity in order to perform peritoneal dialysis on the patient includes a peritoneal cavity monitor (PCM) that measures this volume of fluid in the patient's peritoneal cavity by segmental bioimpedance spectroscopy (SBIS), to thereby determine an ultrafiltration volume of fluid in the patient's peritoneal cavity, and a switch, controlled by the PCM, for filling the patient's peritoneal cavity and draining the patient's peritoneal cavity when the ultrafiltration volume is unchanged over time, significantly decreased, or decreasing at a significant rate.
摘要翻译：腹膜透析（PD）系统，用于将一定体积的PD溶液注入到患者的腹膜腔中以便对患者进行腹膜透析包括腹膜腔监测器（PCM），其通过分段生物阻抗来测量患者腹膜腔内的这种体积的流体光谱学（SBIS），从而确定患者腹膜腔中的液体的超滤体积，以及由PCM控制的开关，用于填充患者的腹膜腔，并且当超滤体积随着时间的推移不变时排出患者的腹膜腔减少或显着降低。

2. 发明公开

EP2754076A2 SYSTEM AND METHOD OF MODELING ERYTHROPOIESIS AND ITS MANAGEMENT 有权
标题翻译：系统和方法进行建模和行政红细胞生成
公开(公告)号：EP2754076A2
公开(公告)日：2014-07-16
申请号：EP12773434.1
申请日：2012-09-07
申请人： Fresenius Medical Care Holdings, Inc.
发明人： FUERTINGER, Doris, Helene , KAPPEL, Franz , KOTANKO, Peter , LEVIN, Nathan, W. , THIJSSEN, Stephan
IPC分类号： G06F19/00
CPC分类号： G06F19/12 , A61K38/1816 , G06F19/00 , G16H50/80
摘要： A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. Optionally, if the patient's hematocrit and/or hemoglobin concentration is not predicted by the model to be in the desired range at the predetermined time, the method includes employing the model with one or more different ESA administration regimens until the model predicts that the patient's hematocrit and/or hemoglobin concentration will be in the desired range at the predetermined time. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a computer system for adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen.

3. 发明公开

EP2627248A2 DRY WEIGHT PREDICTOR 审中-公开
标题翻译：干重预测
公开(公告)号：EP2627248A2
公开(公告)日：2013-08-21
申请号：EP11833309.5
申请日：2011-10-12
申请人： Fresenius Medical Care Holdings, Inc.
发明人： LEVIN, Nathan, W. , ZHU, Fansan
IPC分类号： A61B5/103
CPC分类号： A61B5/0537 , A61B5/6828 , G06F19/3481
摘要： Methods and apparatus for predicting/estimating the dry weight of an individual, e.g., a patient undergoing dialysis treatment, are provided. The techniques employ a bioimpedance measurement (303) on the individual's calf (101) to obtain information regarding the extracellular fluid volume of the calf. Using a measurement of the calf's circumference (309), a resistivity value is calculated, normalized by the individual's body mass index (BMI), and then offset by a reference value to obtain a new variable, DeltanRho, which is shown, by comparison with a "gold standard" (FIGS. 5-9), to be highly effective in predicting/estimating dry weight (FIGS. 10-13 and 15-16). The techniques are easy to use and provide accurate dry weight predictions/estimations without substantially adding to the complexity or cost of dialysis procedures. The techniques can also be used for individuals who are not renal patients, e.g., patients suffering from other diseases in which fluid overload can occur, athletes, fitness enthusiasts, and the like.
摘要翻译：提供了用于预测/估计个体，例如正在进行透析治疗的患者的干重的方法和设备。该技术在个体的小腿（101）上采用生物阻抗测量（303）来获得关于小腿的细胞外液体积的信息。使用小牛的圆周（309）的测量值，电阻率值的计算，由个体的身体质量指数（BMI）归一化，然后通过一个基准值的偏移，以获得一个新的变量，DeltanRho，其被示出，通过与比较 “金标准”（图5-9）在预测/估算干重时非常有效（图10-13和15-16）。这些技术易于使用，并提供准确的干重预测/估算，而不会增加透析程序的复杂性或成本。该技术还可以用于不是肾病人的个体，例如患有可能发生体液过量的其他疾病的患者，运动员，健身爱好者等。

4. 发明授权

EP2858569B1 SYSTEM OF MONITORING AND CONTROL OF ULTRAFILTRATION VOLUME DURING PERITONEAL DIALYSIS USING SEGMENTAL BIOIMPEDANCE 有权
标题翻译：系统监测和控制超滤量在腹膜透析期间使用分段生物氧化
公开(公告)号：EP2858569B1
公开(公告)日：2017-12-06
申请号：EP13800441.1
申请日：2013-06-07
申请人： Fresenius Medical Care Holdings, Inc.
发明人： ZHU, Fansan , LEVIN, Nathan, W.
IPC分类号： A61B5/1455 , A61B5/00 , A61B5/05 , A61B6/00 , A61M1/14 , A61M1/28 , A61M5/142 , G01N21/35 , A61B5/145
CPC分类号： A61M1/28 , A61B5/1451 , A61B5/4848 , A61B5/6866 , A61M1/281 , A61M1/282 , A61M1/284 , A61M2205/17 , A61M2205/18 , A61M2205/3317 , A61M2205/3344 , A61M2205/3379 , A61M2205/3569 , A61M2205/3592 , A61M2210/1017 , A61M2230/005
摘要： A peritoneal dialysis (PD) system for infusing a volume of PD solution into a patient's peritoneal cavity in order to perform peritoneal dialysis on the patient includes a peritoneal cavity monitor (PCM) that measures this volume of fluid in the patient's peritoneal cavity by segmental bioimpedance spectroscopy (SBIS), to thereby determine an ultrafiltration volume of fluid in the patient's peritoneal cavity, and a switch, controlled by the PCM, for filling the patient's peritoneal cavity and draining the patient's peritoneal cavity when the ultrafiltration volume is unchanged over time, significantly decreased, or decreasing at a significant rate.

5. 发明公开

EP2890289A1 DETECTING INDICATIONS OF INTRADIALYTIC MORBID EVENTS BY MEASUREMENT OF RELATIVE BLOOD VOLUME, BLOOD PRESSURE AND HEART RATE 有权
标题翻译：一个透析发病事件的指示通过测量相对血容量，血压和心率检测
公开(公告)号：EP2890289A1
公开(公告)日：2015-07-08
申请号：EP13832003.1
申请日：2013-08-27
申请人： Fresenius Medical Care Holdings, Inc.
发明人： ZHU, Fansan , KOTANKO, Peter , THIJSSEN, Stephan , LEVIN, Nathan, W.
IPC分类号： A61B5/02
CPC分类号： A61B5/746 , A61B5/021 , A61M1/16 , A61M1/1603 , A61M1/1615 , A61M1/341 , A61M1/3413 , A61M1/3609 , A61M2230/06 , A61M2230/30
摘要： A method of detecting an indication of a potential intradialytic morbid event (IME) by monitoring a patient's condition during excess fluid removalby ultrafiltration during a hemodialysis treatment includes determining the patient's relative blood volume (RBV), and removing a portion of the volume of excess fluid from blood of the patient at an initial ultrafiltration rate while periodically monitoring a second derivative over time of the relative blood volume (SDRBV). The method then includes continuing to remove excess fluid from blood of the patient at the same ultrafilration rate, or, optionally, incrementally increasing the ultrafiltration rate. The method further includes triggering an alarm for an IME for the patient if the SDRBV is in a range of between a low SDRBV alarm level and a high SDRBV alarm level, and, alternatively or additionally monitoring the patient's normalized blood pressure ratio, and taking a remedial action if the alarm is triggered.

6. 发明公开

EP2646823A2 METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH 有权
标题翻译：程序用于确定血液透析患者的死亡的危险
公开(公告)号：EP2646823A2
公开(公告)日：2013-10-09
申请号：EP11845234.1
申请日：2011-12-01
申请人： Fresenius Medical Care Holdings, Inc.
发明人： KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
IPC分类号： G01N33/53
CPC分类号： G01N33/5091 , G01N33/6893 , G01N2800/347 , G01N2800/56 , G06F19/00 , Y10T436/147777 , Y10T436/166666
摘要： The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

7. 发明授权

EP2646823B9 METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH 有权
标题翻译： VERFAHREN ZUR BESTIMMUNG DES STERBERISIKOS EINESHÄMODIALYSEPATITENTEN
公开(公告)号：EP2646823B9
公开(公告)日：2017-02-22
申请号：EP11845234.1
申请日：2011-12-01
申请人： Fresenius Medical Care Holdings, Inc.
发明人： KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
IPC分类号： G01N33/68 , G01N33/50
CPC分类号： G01N33/5091 , G01N33/6893 , G01N2800/347 , G01N2800/56 , G06F19/00 , Y10T436/147777 , Y10T436/166666
摘要： The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.
摘要翻译：本发明涉及一种识别接受定期血液透析治疗的患者的方法，所述患者具有增加的死亡风险，其包括确定由血清碳酸氢盐浓度水平，血清钾浓度水平，血清钙浓度水平组成的患者临床或生物化学参数中的至少一个，血红蛋白浓度水平，血清磷浓度水平，嗜中性粒细胞与淋巴细胞比值，平衡标准化蛋白分解代谢率（enPCR），通过透析和残留肾功能平衡的全身水分数（eKdrt / V），EPO抗性指数，转铁蛋白饱和指数，血清铁蛋白浓度水平，血清肌酸酐浓度水平，血小板计数，Aspartat-氨基转移酶水平，以及定期血液透析治疗中的阿拉宁 - 氨基转移酶水平，以及如果患者的发生率发生显着变化，则鉴定患者具有增加的死亡风险的变化至少患者的临床或生物化学参数之一。本发明还涉及一种鉴定进行定期血液透析治疗的患者的死亡危险因素增加的方法。该方法包括分析先前正在进行定期血液透析治疗的死亡患者的数据，在患者的临床或生物化学参数变化的时候进行纵向分析，并确定下降速率或增加率的显着变化在患者死亡前的临床或生物化学参数。

8. 发明授权

EP2646823B1 METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH 有权
标题翻译：程序用于确定血液透析患者的死亡的危险
公开(公告)号：EP2646823B1
公开(公告)日：2016-10-26
申请号：EP11845234.1
申请日：2011-12-01
申请人： Fresenius Medical Care Holdings, Inc.
发明人： KOTANKO, Peter , THIJSSEN, Stephan , USVYAT, Len , LEVIN, Nathan, W.
IPC分类号： G01N33/68 , G01N33/50
CPC分类号： G01N33/5091 , G01N33/6893 , G01N2800/347 , G01N2800/56 , G06F19/00 , Y10T436/147777 , Y10T436/166666
摘要： The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

9. 发明授权

EP1613212B1 DEVICE AND METHOD FOR PERFORMING ELECTRICAL IMPEDANCE TOMOGRAPHY 有权
标题翻译：装置和方法实施电阻抗成像
公开(公告)号：EP1613212B1
公开(公告)日：2016-08-24
申请号：EP04758334.9
申请日：2004-03-25
申请人： Fresenius Medical Care Holdings, Inc.
发明人： ZHU, Fansan , LEVIN, Nathan, W.
IPC分类号： A61B5/053
CPC分类号： A61B5/0536

10. 发明公开

EP1613212A2 DEVICE AND METHOD FOR PERFORMING ELECTRICAL IMPEDANCE TOMOGRAPHY 有权
标题翻译：装置和方法实施电阻抗成像
公开(公告)号：EP1613212A2
公开(公告)日：2006-01-11
申请号：EP04758334.9
申请日：2004-03-25
申请人： Fresenius Medical Care Holdings, Inc.
发明人： ZHU, Fansan , LEVIN, Nathan, W.
IPC分类号： A61B5/05
CPC分类号： A61B5/0536
摘要： A system for performing electrical impedance tomography. The system includes a first set of electrodes positioned in a first plane and a second set of electrodes positioned in a second plane. The system also includes a third set of electrodes positioned in a third plane between the first and second planes. The third set of electrodes is rotatable around an axis intersecting the third plane. Furthermore, the third set of electrodes may be moveable in an axial direction between the first and second planes to various other planes, e.g., a fourth plane, a fifth plane, etc. The processor is further configured to process the voltage measurements taken by the voltage measurement device so as to generate a current density distribution in the various other planes. In addition, the processor is further configured to generate a three-dimensional image corresponding to the current density distribution between the first and second planes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式